Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms NPX372 |
Target |
Mechanism B7-H7 modulators(HERV-H LTR-associating protein 2 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Nextpoint Therapeutics, Inc.Startup |
Active Organization Nextpoint Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Discovery | US | Nextpoint Therapeutics, Inc.Startup | 06 Sep 2024 |